Year: 2022
Type: Article
Title: B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Author: Infante, Maria Stefania
Author: Salmanton-García, Jon
Author: Fernández-Cruz, Ana
Author: Marchesi, Francesco
Author: Jaksic, Ozren
Author: Weinbergerová, Barbora
Author: Besson, Caroline
Author: Duarte, Rafael F
Author: Itri, Federico
Author: Valković, Toni
Author: Szotkovski, Tomáš
Author: Busca, Alessandro
Author: Guidetti, Anna
Author: Glenthøj, Andreas
Author: Collins, Graham P
Author: Bonuomo, Valentina
Author: Sili, Uluhan
Author: Seval, Guldane Cengiz
Author: Machado, Marina
Author: Cordoba, Raul
Author: Blennow, Ola
Author: Abu-Zeinah, Ghaith
Author: Lamure, Sylvain
Author: Kulasekararaj, Austin
Author: Falces-Romero, Iker
Author: Cattaneo, Chiara
Author: Van Doesum, Jaap
Author: Piukovics, Klára
Author: Omrani, Ali S
Author: Magliano, Gabriele
Author: Ledoux, Marie-Pierre
Author: de Ramon, Cristina
Author: Cabirta, Alba
Author: Verga, Luisa
Author: López-García, Alberto
Author: Da Silva, Maria Gomes
Author: Stojanoski, Zlate
Author: Meers, Stef
Author: Lahmer, Tobias
Author: Martín-Pérez, Sonia
Author: Dávila-Vals, Julio
Author: Van Praet, Jens
Author: Samarkos, Michail
Author: Bilgin, Yavuz M
Author: Karlsson, Linda Katharina
Author: Batinić, Josip
Author: Nordlander, Anna
Author: Schönlein, Martin
Author: Hoenigl, Martin
Author: Ráčil, Zdeněk
Author: Mladenović, Miloš
Author: Hanakova, Michaela
Author: Zambrotta, Giovanni Paolo Maria
Author: De Jonge, Nick
Author: Adžić-Vukičević, Tatjana
Author: Nunes-Rodrigues, Raquel
Author: Prezioso, Lucia
Author: Navrátil, Milan
Author: Marchetti, Monia
Author: Cuccaro, Annarosa
Author: Calbacho, Maria
Author: Giordano, Antonio
Author: Cornely, Oliver A
Author: Hernández-Rivas, José-Ángel
Author: Pagano, Livio
Abstract: Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Publisher: Frontiers Media SA
Relation: Frontiers in oncology
Identifier: oai:repository.ukim.mk:20.500.12188/24320
Identifier: 2234-943X
Identifier: http://hdl.handle.net/20.500.12188/24320Identifier: 10.3389/fonc.2022.992137
Identifier: https://www.frontiersin.org/articles/10.3389/fonc.2022.992137/fullIdentifier: 12
